Sanofi Resumes Patient Assistance for Lovenox

by Admin | February 6, 2012 12:38 pm

February 6, 2012—In apparent response to urgent appeals by safety-net providers[1], drug manufacturer Sanofi U.S. has announced that it is reinstating patient assistance for its anti-coagulant Lovenox effective Feb. 15.

The company discontinued its patient assistance program (PAP) for the widely used drug in late December[2]. It also ended its entire institutional patient assistance program (IPAP) at the same time.

 
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[3].    Already registered? Click here to login[4]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

 

Endnotes:
  1. urgent appeals by safety-net providers: https://340binformed.org/2011/12/hospitals-urge-sanofi-to-reinstate-patient-assistance-program/
  2. in late December: https://340binformed.org/2011/12/sanofi-discontinues-its-institutional-patient-assistance-program/
  3. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  4. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2012/02/sanofi-resumes-patient-assistance-for-lovenox/

Copyright ©2025 340binformed.org unless otherwise noted.